What is Axonics?
Founded in 2012 and headquartered in Irvine, California, Axonics is a pioneering medical technology enterprise focused on the development of novel implantable neuromodulation systems. The company addresses critical clinical indications through sophisticated engineering, positioning itself as a leader in the therapeutic device sector. By leveraging advanced neuro-stimulation techniques, Axonics aims to improve patient outcomes and provide sustainable alternatives to traditional treatment modalities within the healthcare landscape.
How much funding has Axonics raised?
Axonics has raised a total of $251.7M across 5 funding rounds:
Series A
$32.6M
Series B
$38.5M
Series C
$20.5M
Series D
$40.1M
Stock Offering
$120M
Series A (2014): $32.6M with participation from Legend Capital, Edmond de Rothschild Investment Partners (EdRIP), and Neomed Management
Series B (2015): $38.5M led by The Alfred E. Mann Foundation, Edmond de Rothschild Investment Partners, Cormorant Asset Management, Legend Capital, Neomed Management, Advent Life Sciences, and Andera Partners
Series C (2017): $20.5M supported by Cormorant Asset Management, CICA, Inc, and Gilde Healthcare
Series D (2018): $40.1M featuring Gilde Healthcare, Silicon Valley Bank, and Longitude Capital
Stock Issuance/Offering (2018): $120M, investors not publicly disclosed
Key Investors in Axonics
Gilde Healthcare
A specialized healthcare investment firm managing over 1.4 billion euros, focusing on venture and growth opportunities that enable better care at lower costs.
Cormorant Asset Management
A prominent life sciences investment firm with over 3 billion dollars in assets under management, driven by a deep focus on fundamental scientific principles.
Neomed Management
An international venture capital firm exclusively focused on the healthcare industry, supporting emerging companies with proprietary medical products.
What's next for Axonics?
With a solid foundation established through successive funding rounds, Axonics is well-positioned to scale its operations and expand its clinical footprint. The strategic deployment of capital will likely prioritize the acceleration of its R&D pipeline and the broadening of its market reach. As the company matures, the focus will shift toward sustaining its competitive advantage in the neuromodulation space, ensuring that its innovative implantable solutions remain at the forefront of medical practice while delivering long-term value to stakeholders and patients alike.
See full Axonics company page
